Anemia is chronically undermanaged in chronic kidney disease (CKD) patients and its etiology is poorly understood. Only 15% and 68% of CKD patients with anemia and severe anemia, respectively, received an official diagnosis; less than a quarter of diagnosed anemic patients and less than half of diagnosed severely anemic patients received treatment. The treatment goal of anemia is an increase in iron measures, yet safety concerns surround treatment options and leave guidelines nebulous. The benefits of options such as oral iron, intravenous iron, and erythropoiesis-stimulating agent (ESA) therapy must furthermore be balanced against significant adverse effects. A novel agent class known as hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) expands anemia treatment options for dialysis-dependent (DD) CKD patients; its optimization, however, is reliant on adequate knowledge. It is thus imperative that clinicians are appraised on this emerging agent class.
In the second activity of this CME Outfitters BriefCase series, expert faculty utilize case-based learning to utilize the latest data on novel therapies in clinical decision-making and guide learners through how best to address unmet needs in the treatment of anemia due to CKD.
Utilize the latest data on novel therapies in clinical decision-making to address unmet needs in the treatment of anemia due to CKD
This educational activity is supported by an educational grant from GSK.
Physicians, physician associates (PAs), nurse practitioners (NPs), nurses, and pharmacists specializing in nephrology or primary care
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.
Dr. Singh reports the following financial relationships:
Consultant: Allucent; Bayer; Chinook Therapeutics Inc.; Entrada Therapeutic, Inc.; GSK; Nephrology Times; and Zydus Pharmaceuticals, Inc.
Disclosures were obtained from the following CME Outfitters, LLC, staff, with no disclosures to report:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Call us at 877.CME.PROS (877.263.7767).